0000000000418201

AUTHOR

Sola Patrizia

showing 3 related works from this author

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multice…

2021

none 38 no BACKGROUND: Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). However, patients and physicians may consider discontinuing NTZ therapy due to safety or efficacy issues. The aim of our study was to evaluate the NTZ discontinuation rate and reasons of discontinuation in a large Italian population of RRMS patients. MATERIALS AND METHODS: The data were extracted from the Italian MS registry in May 2018 and were collected from 51,845 patients in 69 Italian multiple sclerosis centers. MS patients with at least one NTZ infusion in the period between June 1st 2012 to May 15th 2018 were included. Discontinuation rates at each time point were cal…

Adultmedicine.medical_specialtyDiscontinuation rateNeurologyReasons for discontinuationPopulationProgressive MultifocalRelapsing-RemittingSettore MED/26Multiple sclerosis03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingLeukoencephalopathyInternal medicineparasitic diseasesmedicineEffective treatmentHumansImmunologic FactorsMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDiscontinuation rate; Multiple sclerosis; Natalizumab; Reasons for discontinuation; Adult; Female; Humans; Immunologic Factors; Middle Aged; Natalizumab; Retrospective Studies; Leukoencephalopathy Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis Relapsing-Remittingbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyNatalizumabLeukoencephalopathy Progressive MultifocalRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic mod…

Male0301 basic medicineDimethyl FumarateNeurodegenerativemultiple sclerosis; coronavirus; pneumoniaSeverity of Illness Indexlaw.inventionImmunosuppressive AgentImmunologic Factor0302 clinical medicineNatalizumablawMonoclonalMultiple Sclerosi80 and overLungHumanizedResearch ArticlesAged 80 and overNatalizumabMiddle AgedIntensive care unitHospitalizationSettore MED/26 - NEUROLOGIAIntensive Care UnitsNeurologyMethylprednisoloneNeurologicalPneumonia & InfluenzaInterferonFemaleImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMusc-19 Study GroupMultiple SclerosisAdolescentClinical SciencesIntensive Care UnitClinical NeurologySettore MED/26Antibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesYoung Adult03 medical and health sciencesClinical ResearchInternal medicineSeverity of illnessmedicineHumansImmunologic FactorsMortalityAdolescent; Adult; Aged; Aged 80 and over; Antibodies Monoclonal Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young AdultAgedNeurology & NeurosurgeryExpanded Disability Status ScaleFingolimod HydrochlorideSARS-CoV-2business.industryMultiple sclerosisNeurosciencesCOVID-19PneumoniaOdds ratiomedicine.diseaseBrain DisordersGood Health and Well Being030104 developmental biologyOcrelizumabInterferonsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population.

2012

It has been recently reported that a large proportion of patients with familial amyotrophic lateral sclerosis (familial ALS) and frontotemporal dementia (FTD) are associated with a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72. We have assessed 1,757 Italian sporadic ALS cases, 133 from Sardinia, 101 from Sicily, and 1,523 from mainland Italy. Sixty (3.7%) of 1,624 mainland Italians and Sicilians and 9 (6.8%) of the 133 Sardinian sporadic ALS cases carried the pathogenic repeat expansion. None of the 619 regionally-matched control samples (1,238 chromosomes) carried the expansion. Twenty-five cases (36.2%) had behavioral FTD in addition to ALS. FTD or unspecified d…

MaleAgingSurvivalPedigree chartSettore MED/03 - GENETICA MEDICARepetitive Sequences0302 clinical medicineC9orf72Polymorphism (computer science)Risk FactorsPrevalenceAmyotrophic lateral sclerosisGenetics0303 health scienceseducation.field_of_studyGeneral NeuroscienceSingle NucleotideMiddle Aged3. Good healthSettore MED/26 - NEUROLOGIAItalyFemaleSettore MED/26 - NeurologiaFrontotemporal dementiaFrontotemporal dementiaGenetic MarkersPopulationC9ORF72BiologyPolymorphism Single NucleotideArticle03 medical and health sciencesmedicineHumansGenetic Predisposition to DiseasePolymorphismeducationamyotrophic lateral sclerosis; C9orf672; frontotemporal dementia; survivalAmyotrophic lateral sclerosi030304 developmental biologyRepetitive Sequences Nucleic AcidAmyotrophic lateral sclerosis; C9ORF72; sporadicC9orf72 ProteinNucleic AcidAmyotrophic lateral sclerosis C9ORF72 Frontotemporal dementia SurvivalGenetic VariationProteinsmedicine.diseaseAmyotrophic lateral sclerosisC9orf672C9orf72 ProteinAmyotrophic lateral sclerosis; C9ORF72; Frontotemporal dementia; Survival;Settore BIO/18 - GeneticasporadicNeurology (clinical)Geriatrics and GerontologyALSTrinucleotide repeat expansion030217 neurology & neurosurgeryDevelopmental Biology
researchProduct